Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?

Figure 1 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cancers, Free Full-Text

Ipilimumab Plus Nivolumab Improves Survival in Melanoma With Brain Metastases - Cancer Therapy Advisor

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses